Abstract
The synthesis of pyrazolo[3,4-f]quinoline-8-carbonitriles 4a–h and 6a–k involves the reaction of an aromatic aldehyde, 1H-indazol-6-amine and 3-(1H-indol-3-yl)-3-oxopropanenitrile or 3-oxo-3-arylpropanenitrile in ethanol under mild conditions.
Introduction
Multi-component domino reactions (MDRs), as the effective approach to improve synthetic efficiency, have been successfully applied to the synthesis of various heterocycles. These reactions can involve high levels of diversity giving rise to complex structures by simultaneous formation of three or more bonds from simple substrates [1], [2], [3]. Such transformations can avoid tedious steps of protection and deprotection of functional groups and isolation of intermediates, thereby dramatically reducing production of waste. Recently, various MDRs have efficiently been used for the construction of heterocyclic compounds with biological activities [4], [5], [6].
The indole moiety has been found in various biologically active compounds [[7], [[8]. Many indole alkaloids are recognized as one of the rapidly growing groups of marine invertebrate metabolites for their broad spectrum of biological properties 9], [10], such as anticancer, anti-tumour 11], anti-inflammatry, hypoglycemic, analgesic and antipyretic activities. On the other hand, pyrazole-fused quinolines are also useful heterocycles that possess various bioactivities including antimalarial [12], analgesic [13], antipsychotic [14] and antimicrobial properties [15]. Many procedures have been reported to synthesize such compounds in the past few years [16], [17], [18].
In continuation of our interest in the synthesis of new heterocyclic compounds by one-pot multicomponent reactions [19], [20], [21], herein we report an efficient synthetic approach to substituted pyrazolo[3,4-f]quinolines 4a–h and 6a–k (Schemes 1 and 2). The synthesis was conducted by reacting an aromatic aldehyde, 1H-indazol-6-amine and 3-(1H-indol-3-yl)-3-oxopropanenitrile or 3-oxo-3-phenylpropanenitrile in ethanol in the absence of any metal catalyst.


Results and discussion
Our initial investigations focused on the three-component reaction of 1H-indazol-6-amine (1), benzaldehyde (2a) and 3-(1H-indol-3-yl)-3-oxopropanenitrile (3) as a simple model for optimization of the reaction conditions (Scheme 1).
In the absence of any catalyst, the reaction conducted under reflux conditions furnished product 4a in the yield of 88%. Different bases, including NaOH, NaHCO3, piperidine and Et3N, were used in an attempt to promote the reaction. However, under these conditions the yield of 4a was not improved. Other solvents, including methanol, tetrahydrofuran, acetonitrile and dioxane, were also tested but ethanol proved to be superior. Furthermore, the analytically pure product precipitated from the ethanolic solution upon cooling the mixture.
With the optimized reaction conditions in hand, commercially available aromatic aldehydes 2 bearing either electron-withdrawing or electron-donating functional groups such as chloro, bromo, nitro and alkyl, were all found to be suitable for the reaction with 1H-indazol-6-amine (1) and 3-(1H-indol-3-yl)-3-oxopropanenitrile (3) to obtain pyrazolo[3,4-f]quinoline derivatives. It was noted that aromatic aldehydes with an electron-donating group always require more time to react. The reaction of 3-oxo-3-phenylpropanenitrile (5) with aromatic aldehydes 2 and 1H-indazol-6-amine also furnished the expected pyrazolo[3,4-f]quinoline-8-carbonitriles 6a–k in high yields (Scheme 2). All products were characterized by 1H NMR, 13C NMR, IR and HRMS spectral data.
A plausible reaction mechanism for this reaction is illustrated in Scheme 3 using 3-oxo-3-arylpropanenitrile (5) as the substrate. The initial Knoevenagel condensation between 2 and 5 generates an intermediate product A. Then another intermediate product B is generated in the Michael addition reaction of 1H-indazol-6-amine (1) to A. Compound B undergoes tautomerization to C, the intramolecular cyclization-dehydration of which generates the final intermediate product D which is the direct precursor to the observed pyrazolo[3,4-f]quinoline 6.

Conclusion
A highly efficient method for the synthesis of 6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile derivatives was developed. This procedure has several attractive characteristics such as ready availability of starting materials, mild reaction conditions, high yields and operational simplicity.
Experimental
Melting points were determined in open capillaries and are uncorrected. IR spectra were taken on a Fourier-transform infrared (FT-IR)-Tensor 27 spectrometer in KBr pellets. 1H NMR spectra (400 MHz) and 13C NMR spectra (100 MHz) were measured on a Bruker DPX spectrometer in DMSO-d6. 1H NMR and 13C NMR spectra for all compounds 4a–h, 6a–k are shown in supplementary material. The exact mass measurements were carried out using a Bruker micro-TOF-Q-MS analyzer.
General procedure for the synthesis of compounds 4a–4h and 6a–6k
A dry 50-mL flask was charged with 1H-indazol-6-amine 1 (1.0 mmol), aromatic aldehyde 2 (1.0 mmol), 3-(1H-indol-3-yl)-3-oxopropanenitrile 3 (1.0 mmol) or 3-oxo-3-arylpropanenitrile 5 (1.0 mmol) and EtOH (10 mL). The mixture was stirred at reflux for 3–8 h. After completion of the reaction, as indicated by thin-layer chromatography, the solid product 4 or 6 was obtained after the mixture was cooled to room temperature.
7-(1H-Indol-3-yl)-9-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (4a)
White powder; yield 88%; mp >300°C; 1H NMR: δ 12.87 (s, 1H, NH), 11.74 (s, 1H, NH), 9.83 (s, 1H, NH), 7.98 (s, 1H, ArH), 7.83 (d, J=2.7 Hz, 1H, ArH), 7.59 (d, J=8.6 Hz, 1H, ArH), 7.55–7.43 (m, 4H, ArH), 7.35–7.32 (m, 2H, ArH), 7.23–7.20 (m, 2H, ArH), 7.15–7.12 (m, 1H, ArH), 7.05 (d, J=8.6 Hz, 1H, ArH), 5.29 (s, 1H, CH); 13C NMR: δ 146.3, 145.6, 136.5, 135.1, 129.0, 127.8, 127.5, 127.4, 125.7, 122.9, 122.5, 120.4, 120.3, 112.6, 112.5, 108.9, 103.2, 78.1, 56.5, 41.1, 19.0; IR: 3459, 3351, 3252, 218.05, 1632, 1604, 1538, 1490, 1440, 1340, 1235, 937, 745 cm−1. ESI-HR-MS. Calcd for C25H17N5 ([M-H]−): m/z 386.1406. Found: m/z 386.1396.
9-(4-Chlorophenyl)-7-(1H-indol-3-yl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (4b)
White powder; yield 80%; mp >300°C; 1H NMR: δ 12.90 (s, 1H, NH), 11.77 (s, 1H, NH), 9.89 (s, 1H, NH), 8.01 (s, 1H, ArH), 7.86 (d, J=2.8 Hz, 1H, ArH), 7.62 (d, J=8.6 Hz, 1H, ArH), 7.56–7.48 (m, 4H, ArH), 7.43 (d, J=8.5 Hz, 2H, ArH), 7.24–7.21 (m, 1H, ArH), 7.17–7.14 (m, 1H, ArH), 7.08 (d, J=8.6 Hz, 1H, ArH), 5.35 (s, 1H, CH); 13C NMR: δ 153.8, 152.0, 145.7, 145.1, 136.5, 135.1, 132.1, 131.0, 129.3, 129.1, 127.9, 125.6, 122.7, 122.5, 121.2, 120.6, 120.4, 113.3, 112.6, 108.8, 102.7, 77.8, 40.5; IR: 3402, 3270, 2193, 1635, 1610, 1537, 1489, 1445, 1340, 1233, 932, 745 cm−1. ESI-HR-MS. Calcd for C25H16ClN5 ([M-H]−): m/z 420.1016. Found: m/z 420.1015.
7-(1H-Indol-3-yl)-9-(4-nitrophenyl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (4c)
Yellow powder; yield 81%; mp >300°C; 1H NMR: δ 12.96 (s, 1H, NH), 11.79 (s, 1H, NH), 10.00 (s, 1H, NH), 8.26 (d, J=8.8 Hz, 2H, ArH), 8.01 (s, 1H, ArH), 7.87 (d, J=2.8 Hz, 1H, ArH), 7.72 (d, J=8.8 Hz, 2H, ArH), 7.65 (d, J=8.6 Hz, 1H, ArH), 7.56–7.52 (m, 2H, ArH), 7.24–7.21 (m, 1H, ArH), 7.17–7.10 (m, 2H, ArH), 5.52 (s, 1H, CH); 13C NMR: δ 153.0, 147.0, 146.1, 136.5, 128.7, 128.0, 125.6, 124.5, 122.5, 122.4, 121.0, 120.5, 120.4, 112.6, 108.6, 76.9, 41.1; IR: 3409, 3226, 2199, 1637, 1605, 1540, 1493, 1447, 1341, 1233, 935, 749 cm−1. ESI-HR-MS. Calcd for C25H16N6O2 ([M-H]−): m/z 431.1256. Found: m/z 431.1257.
7-(1H-Indol-3-yl)-9-(p-tolyl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (4d)
White crystals; yield 86%; mp 268–270°C; 1H NMR: δ 12.83 (s, 1H, NH), 11.74 (s, 1H, NH), 9.79 (s, 1H, NH), 7.97 (s, 1H, ArH), 7.82 (d, J=2.7 Hz, 1H, ArH), 7.58–7.51 (m, 3H, ArH), 7.38 (d, J=8.0 Hz, 2H, ArH), 7.23–7.20 (m, 1H, ArH), 7.15–7.12 (m, 3H, ArH), 7.04 (d, J=8.6 Hz, 1H, ArH), 5.24 (s, 1H, CH), 2.24 (s, 3H, CH3); 13C NMR: δ 145.4, 143.5, 136.5, 135.0, 129.6, 127.7, 127.5, 125.7, 122.9, 122.5, 120.4, 120.2, 112.6, 112.5, 109.0, 103.5, 78.3, 56.6, 40.7, 21.1, 19.0; IR: 3337, 3258, 2186, 1632, 1608, 1538, 1489, 1441, 1341, 1235, 933, 751 cm−1. ESI-HR-MS. Calcd for C26H19N5 ([M-H]−): m/z 400.1562. Found: m/z 400.1559.
7-(1H-Indol-3-yl)-9-(4-methoxyphenyl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (4e)
White crystals; yield 79%; mp 270–273°C; 1H NMR: δ 12.84 (s, 1H, NH), 11.73 (s, 1H, NH), 9.78 (s, 1H, NH), 7.97 (s, 1H, ArH), 7.82 (d, J=2.7 Hz, 1H, ArH), 7.58–7.50 (m, 3H, ArH), 7.41 (d, J=8.6 Hz, 2H, ArH), 7.23–7.19 (m, 1H, ArH), 7.17–7.12 (m, 1H, ArH), 7.03 (d, J=8.6 Hz, 1H, ArH), 6.89 (d, J=8.7 Hz, 2H, ArH), 5.23 (s, 1H, CH), 3.71 (s, 3H, CH3); 13C NMR: δ 158.7, 145.3, 138.6, 136.5, 134.9, 134.6, 133.3, 128.6, 127.7, 125.7, 122.9, 122.4, 120.4, 120.3, 120.1, 115.2, 114.4, 112.6, 112.5, 109.0, 103.6, 78.5, 55.5; IR: 3382, 3254, 2197, 1635, 1605, 1535, 1492, 1446, 1340, 1235, 938, 746 cm−1. ESI-HR-MS. Calcd for C26H19N5O ([M-H]−): m/z 416.1511. Found: m/z 416.1501.
9-(3-Chlorophenyl)-7-(1H-indol-3-yl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (4f)
White powder; yield 84%; mp 295–296°C; 1H NMR: δ 12.95 (s, 1H, NH), 11.79 (s, 1H, NH), 9.93 (s, 1H, NH), 8.02 (s, 1H, ArH), 7.88 (d, J=2.8 Hz, 1H, ArH), 7.64 (d, J=8.6 Hz, 1H, ArH), 7.55 (t, J=7.8 Hz, 3H, ArH), 7.46–7.37 (m, 2H, ArH), 7.31 (d, J=7.9 Hz, 1H, ArH), 7.23 (t, J=7.6 Hz, 1H, ArH), 7.16 (t, J=7.5 Hz, 1H, ArH), 7.09 (d, J=8.6 Hz, 1H, ArH), 5.35 (s, 1H, CH); 13C NMR: δ 148.5, 145.9, 136.5, 135.1, 133.6, 131.1, 127.9, 127.4, 127.2, 126.3, 125.6, 122.6, 122.5, 120.7, 120.4, 120.3, 112.7, 112.6, 108.7, 102.5, 77.5, 40.9; IR: 3418, 3234, 2209, 1634, 1610, 1536, 1490, 1449, 1350, 1233, 936, 750 cm−1. ESI-HR-MS. Calcd for C25H16ClN5 ([M-H]−): m/z 420.1016. Found: m/z 420.1000.
9-(3-Bromophenyl)-7-(1H-indol-3-yl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (4g)
White powder; yield 81%; mp >300°C; 1H NMR: δ 12.95 (s, 1H, NH)), 11.78 (s, 1H, NH), 9.93 (s, 1H, NH), 8.02 (s, 1H, ArH), 7.87 (d, J=2.8 Hz, 1H, ArH), 7.70 (s, 1H, ArH), 7.63 (d, J=8.6 Hz, 1H, ArH), 7.56–7.53 (m, 2H, ArH), 7.48–7.43 (m, 2H, ArH), 7.34–7.31 (m, 1H, ArH), 7.24–7.21 (m, 1H, ArH), 7.17–7.14 (m, 1H, ArH), 7.08 (d, J=8.6 Hz, 1H, ArH), 5.32 (s, 1H, CH); 13C NMR: δ 148.5, 145.9, 136.5, 135.1, 131.5, 130.3, 130.1, 127.9, 126.7, 125.6, 122.6, 122.5, 122.4, 120.7, 120.4, 120.3, 112.7, 112.6, 108.7, 102.5, 77.6, 40.9; IR: 3406, 3237, 2209, 1634, 1610, 1536, 1491, 1449, 1350, 1234, 936, 750 cm−1. ESI-HR-MS. Calcd for C25H16BrN5 ([M-H]−): m/z 464.0511. Found: m/z 464.0521.
9-(3,4-Dichlorophenyl)-7-(1H-indol-3-yl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (4h)
White powder; yield 83%; mp 295–296°C; 1H NMR: δ 12.93 (s, 1H, NH), 11.79 (s, 1H, NH), 9.95 (s, 1H, NH), 8.02 (s, 1H, ArH), 7.88 (d, J=2.8 Hz, 1H, ArH), 7.72 (d, J=2.1 Hz, 1H, ArH), 7.64 (d, J=8.3 Hz, 2H, ArH), 7.56–7.52 (m, 2H, ArH), 7.42–7.40 (m, 1H, ArH), 7.24–7.21 (m, 1H, ArH), 7.18–7.15 (m, 1H, ArH), 7.08 (d, J=8.6 Hz, 1H, ArH), 5.35 (s, 1H, CH); 13C NMR: δ 153.7, 150.4, 146.9, 145.9, 136.9, 136.5, 135.0, 131.6, 130.1, 128.0, 126.7, 125.6, 123.0, 122.7, 122.5, 120.9, 120.5, 120.3, 112.6, 108.6, 102.1, 77.2; IR: 3422, 3216, 2201, 1635, 1606, 1538, 1486, 1458, 1340, 1231, 936, 746 cm−1. ESI-HR-MS. Calcd for C25H15Cl2N5 ([M-H]−): m/z 454.0626. Found: m/z 454.0607.
7,9-Diphenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6a)
White powder; yield 84%; mp 172–184°C; 1H NMR: δ 12.85 (s, 1H, NH), 9.95 (s, 1H, NH), 7.96 (s, 1H), 7.64–7.58 (m, 3H, ArH), 7.56 (m, 4H, ArH), 7.44 (d, J=7.7 Hz, 2H, ArH), 7.32 (m, 2H, ArH), 7.20 (m, 1H, ArH), 7.01 (d, J=8.6 Hz, 1H, ArH), 5.27 (s, 1H, CH); 13C NMR: δ 150.6, 145.8, 138.5, 134.8, 134.7, 134.2, 130.8, 129.1, 129.0, 128.9, 127.6, 127.5, 121.9, 120.6, 120.5, 112.4, 102.8, 79.3, 56.5, 41.0, 19.0; IR: 3273, 2191, 1633, 1607, 1540, 1495, 1355, 1283, 945, 917, 726 cm−1. ESI-HR-MS. Calcd for C23H16N4 ([M-H]−): m/z 347.1297. Found: m/z 347.1280.
9-(4-Chlorophenyl)-7-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6b)
White powder; yield 80%; mp 221–226°C; 1H NMR: δ 12.87 (s, 1H, NH), 10.00 (s, 1H, NH), 7.98 (s, 1H, ArH), 7.59 (m, 6H, ArH), 7.42 (d, J=10.5 Hz, 4H, ArH), 7.02 (d, J=8.2 Hz, 1H, ArH), 5.31 (s, 1H, CH); 13C NMR: δ 150.2, 144.1, 138.0, 134.3, 133.6, 131.7, 130.4, 129.0, 128.6, 128.4, 121.2, 120.3, 120.1, 111.9, 101.7, 78.5; IR: 3294, 2185, 1629, 1599, 1533, 1497, 1357, 1283, 945, 916, 781 cm−1. ESI-HR-MS. Calcd for C23H15ClN4 ([M-H]−): m/z 381.0907. Found: m/z 381.0891.
9-(4-Nitrophenyl)-7-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6c)
Yellow powder; yield 81%; mp 246–249°C; 1H NMR: δ 12.93 (s, 1H, NH), 10.11 (s, 1H, NH), 8.23 (d, J=8.5 Hz, 2H, ArH), 7.99 (s, 1H, ArH), 7.70–7.57 (m, 8H, ArH), 7.05 (d, J=8.6 Hz, 1H, ArH), 5.49 (s, 1H, CH); 13C NMR: δ 152.3, 151.2, 147.1, 138.5, 134.9, 134.8, 133.9, 131.0, 129.1, 128.9, 128.8, 124.5, 121.5, 121.2, 120.7, 112.5, 101.4, 78.2, 40.9; IR: 3471, 3385, 3259, 2192, 1634, 1605, 1540, 1509, 1350, 1276, 947, 914, 772 cm−1. ESI-HR-MS. Calcd for C23H15N5O2 ([M-H]−): m/z 392.1147. Found: m/z 392.1136.
7-Phenyl-9-(p-tolyl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6d)
White crystals; yield 86%; mp 232–234°C; 1H NMR: δ 12.83 (s, 1H, NH), 9.92 (s, 1H, NH), 7.96 (s, 1H, ArH), 7.61–7.56 (m, 6H, ArH), 7.37 (d, J=8.0 Hz, 2H, ArH), 7.00 (d, J=8.5 Hz, 1H, ArH), 6.88 (d, J=7.9 Hz, 2H, ArH), 5.22 (s, 1H, CH), 3.69 (s, 3H, CH3); 13C NMR: δ 151.1, 143.7, 139.2, 137.4, 135.4, 135.3, 135.0, 131.5, 130.3, 129.8, 129.6, 128.2, 122.6, 121.2, 121.1, 113.1, 103.7, 80.2, 57.2, 21.8; IR: 3385, 3257, 2192, 1634, 1605, 1576, 1509, 1350, 1276, 947, 914, 772 cm−1. ESI-HR-MS. Calcd for C24H18N4 ([M-H]−): m/z 361.1453. Found: m/z 361.1458.
9-(4-Methoxyphenyl)-7-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6e)
White powder; yield 79%; mp 170–174°C; 1H NMR: δ 12.83 (s, 1H, NH), 9.94 (s, 1H, NH), 7.96 (s, 1H, ArH), 7.60–7.56 (m, 6H, ArH), 7.33 (d, J=7.7 Hz, 2H, ArH), 7.12 (d, J=7.6 Hz, 2H, ArH), 7.00 (d, J=8.5 Hz, 1H, ArH), 5.23 (s, 1H, CH), 2.23 (s, 3H, CH3); 13C NMR: δ 158.8, 150.3, 138.5, 138.2, 134.7, 134.3, 130.8, 129.1, 128.9, 128.7, 122.0, 120.5, 120.4, 114.4, 112.4, 103.2, 79.7, 55.5; IR: 3275, 2191, 1634, 1605, 1537, 1495, 1346, 1279, 947, 914, 773 cm−1; ESI-HR-MS. Calcd for C24H18N4O ([M-H]−): m/z 377.1402. Found: m/z 377.1400.
9-(3-Chlorophenyl)-7-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6f)
White powder; yield 84%; mp 188–191°C; 1H NMR: δ 12.91 (s, 1H, NH), 10.04 (s, 1H, NH), 8.00 (s, 1H, ArH), 7.66–7.57 (m, 7H, ArH), 7.44–7.39 (m, 2H, ArH), 7.32–7.28 (m, 1H, ArH), 7.04 (d, J=8.6 Hz, 1H, ArH), 5.30 (s, 1H, CH);13C NMR: δ 150.9, 148.2, 138.4, 134.8, 134.7, 134.0, 131.6, 131.0, 130.5, 130.1, 129.2 128.9, 126.8, 122.4, 121.7, 120.9, 120.7, 112.4, 102.0, 78.8, 40.8; IR: 3379, 3284, 2194, 1632, 1612, 1564, 1540, 1492, 1354, 1277, 945, 911, 767 cm−1. ESI-HR-MS. Calcd for C23H15ClN4 ([M-H]−): m/z 381.0907 Found: m/z 381.0897.
9-(3-Bromophenyl)-7-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6g)
White powder; yield 81%; mp 252–255°C; 1H NMR: δ 12.92 (s, 1H, NH), 10.05 (s, 1H, NH), 8.00 (s, 1H, ArH), 7.67–7.57 (m, 7H, ArH), 7.44–7.40 (m, 2H, ArH), 7.33–7.29 (m, 1H, ArH), 7.04 (d, J=8.5 Hz, 1H, ArH), 5.31 (s, 1H, CH); 13C NMR: δ 150.4, 147.7, 137.9, 134.3, 133.5, 131.0, 130.5, 130.0, 129.7, 128.7, 128.4, 126.3, 121.9, 121.2, 120.4, 120.2, 111.9, 101.5, 78.3, 40.3; IR: 3373, 3222, 2189, 1633, 1606, 1570, 1540, 1500, 1351, 1274, 945, 917, 797 cm−1. ESI-HR-MS. Calcd for C23H15BrN4 ([M-H]−): m/z 425.0402. Found: m/z 425.0403.
9-(2-Chlorophenyl)-7-(1H-indol-3-yl)-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6h)
White powder; yield 83%; mp 261–264°C; 1H NMR: δ 12.20 (s, 1H, NH), 10.05 (s, 1H, NH), 7.97 (s, 1H, ArH), 7.61–7.54 (m, 7H, ArH), 7.44–7.42 (m, 1H, ArH), 7.33–7.27 (m, 2H, ArH), 6.97 (d, J=8.6 Hz, 1H, ArH), 5.76 (s, 1H, CH); 13C NMR: δ 151.4, 140.8, 138.7, 135.9, 135.0, 134.3, 133.2, 131.9, 131.0, 130.8, 129.5, 129.1, 128.8, 127.8, 121.4, 121.0, 120.8, 112.2, 100.7, 77.2, 56.5, 40.6, 19.0; IR: 3416, 3260, 2191, 1633, 1607, 1536, 1496, 1346, 1276, 942, 914, 773 cm−1. ESI-HR-MS. Calcd for C23H15ClN4 ([M-H]−): m/z 381.0907. Found: m/z 381.0902.
9-(2-Methoxyphenyl)-7-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6i)
White powder; yield 74%; mp 155–157°C; 1H NMR: δ 7.89 (s, 1H, ArH), 7.67 (d, J=7.6 Hz, 2H, ArH), 7.49–7.45 (m, 5H, ArH), 7.00–6.98 (s, 2H, ArH), 6.75 (s, 1H, ArH), 6.63 (d, J=8.5 Hz, 1H, ArH), 5.83 (s, 1H, CH), 4.09 (s, 3H, CH3); 13C NMR: δ 154.4, 150.1, 139.0, 135.1, 134.1, 133.4, 133.3, 130.7, 130.4, 129.1, 128.9, 127.8, 122.9, 120.3, 120.1, 112.2, 111.7, 103.5, 77.4, 77.1, 76.8, 33.6, 18.4; IR: 3278, 3416, 2190, 1634, 1607, 1535, 1493, 1350, 1280, 945, 914, 756 cm−1. ESI-HR-MS. Calcd for C24H18N4O ([M-H]−): m/z 377.1402. Found: m/z 377.1398.
9-(3,4-Dichlorophenyl)-7-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6j)
White powder; yield 82%; mp 184–186°C; 1H NMR: δ 12.89 (s, 1H, NH), 10.06 (s, 1H, NH), 8.00 (s, 1H, ArH), 7.70–7.57 (m, 8H, ArH), 7.35 (d, J=8.3 Hz, 1H, ArH), 7.04 (d, J=8.6 Hz, 1H, ArH), 5.33 (s, 1H, CH); 13C NMR: δ 151.0, 146.3, 138.4, 134.9, 134.8, 134.0, 131.7, 131.5, 131.0, 130.3, 129.3, 129.2, 128.9, 128.2, 121.5, 121.1, 120.7, 112.4, 101.6, 78.5, 56.5, 19.0; IR: 3265, 3212, 2196, 1633, 1604, 1537, 1500, 1346, 1276, 944, 918, 772 cm−1. ESI-HR-MS. Calcd for C23H14Cl2N4 ([M-H]−): m/z 415.0517. Found: m/z 415.0543.
9-(4-(Furan-2-yl)phenyl)-7-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f]quinoline-8-carbonitrile (6k)
White powder; yield 85%; mp >300 °C; 1H NMR: δ 12.94 (s, 1H, NH), 9.99 (s, 1H, NH), 7.99 (s, 1H, ArH), 7.59 (m, 7H, ArH), 6.96 (d, J=8.6 Hz, 1H, ArH), 6.36 (s, 2H, ArH), 5.51 (s, 1H, CH); 13C NMR: δ 155.9, 151.8, 143.2, 138.6, 135.0, 134.5, 134.1, 131.0, 129.2, 129.0, 121.7, 120.7, 120.5, 112.3, 110.9, 106.5, 100.0, 75.0, 34.9; IR: 3321, 2187, 1633, 1606, 1531, 1496, 1355, 1276, 945, 907, 761 cm−1. ESI-HR-MS. Calcd for C27H18N4O ([M-H]−): m/z 413.1402. Found: m/z 413.1405.
Acknowledgments
The authors thank the Science Research and Development Foundation of the Kangda College of Nanjing Medical University (grants KD2017KYJJYB004, KD2017KYJJZD004, KD2017KYJJYB003 and KD2015KYJJZD001), Qing Lan Project and theConstruction FoundationofNationalInnovativeCityofLianyungang (No. SH1514) for financial support.
References
[1] Isambert, N.; Lavilla, R. Heterocycles as key substrates in multicomponent reactions: the fast lane towards molecular complexity. Chem. Eur. J.2008, 14, 8444–8454.10.1002/chem.200800473Search in Google Scholar
[2] Sunderhaus, J. D.; Martin, S. F. Applications of multicomponent reactions to the synthesis of diverse heterocyclic scaffolds. Chem. Eur. J.2009, 15, 1300–1308.10.1002/chem.200802140Search in Google Scholar
[3] Ganem, B. Strategies for innovation in multicomponent reaction design. Acc. Chem. Res. 2009, 42, 463–472.10.1021/ar800214sSearch in Google Scholar
[4] Wang, L.; Shi, L. X.; Liu, Lu.; Li, Z. X.; Xu, T.; Hao, W. J.; Li, G.; Tu, S. J.; Jiang, B. Synthesis of diastereo-enriched oxazolo[5,4-b]indoles via catalyst-free multicomponent bicyclizations. J. Org. Chem.2017, 82, 3605.10.1021/acs.joc.7b00129Search in Google Scholar
[5] Fan, W.; Li, Y. R.; Jiang, B.; Li, G. Cascade bicyclization of triethylammonium thiolates with hydrazines: efficient access to pyrazolo[3,4-c]quinolines. Org. Biomol. Chem. 2016, 14, 9080.10.1039/C6OB01728BSearch in Google Scholar
[6] Jiang, B.; Zhang, T. S.; Fu, R.; Hao, W. J.; Wang, S. L.; Tu, S. J. A multi-component domino bicyclization strategy: direct access to skeletally diverse quinazoline collection. Tetrahedron2016, 72, 5652–5658.10.1016/j.tet.2016.07.074Search in Google Scholar
[7] Gribble, G.W. Recent developments in indole ring synthesis- methodology and applications. J Chem Soc Perkin Trans. 2000, 1, 1045–1047.10.1039/a909834hSearch in Google Scholar
[8] Xiong, W. N.; Yang, C. G.; Jiang, B. Synthesis of novel analogues of marine indole alkaloids: mono(indolyl)-4-trifluoromethylpyridines and bis(indolyl)-4-trifluoromethylpyridines as potential anticancer agents. Bioorg. Med. Chem.2001, 9, 1773–1780.10.1016/S0968-0896(01)00070-0Search in Google Scholar
[9] Kouko, T.; Matsumura, K.; Kawasaki, T. Total synthesis of marine bisindole alkaloids, (+)-hamacanthins A, B and (-)-antipode of cis-dihydrohamacanthin B. Tetrahedron2005, 61, 2309–2318.10.1016/j.tet.2005.01.058Search in Google Scholar
[10] Kaniwa, K.; Arai, M. A.; Li, X.; Ishibashi, M.; Synthesis, determination of stereochemistry, and evaluation of new bisindole alkaloids from the myxomycete Arcyria ferruginea: an approach for Wnt signal inhibitor. Bioorg. Med. Chem. Lett. 2007, 17, 4254–4257.10.1016/j.bmcl.2007.05.033Search in Google Scholar PubMed
[11] Zhu, S. L.; Ji, S. J.; Su, X. M.; Sun, C.; Liu, Y. ChemInform abstract: facile and efficient synthesis of a new class of bis(3-indolyl)pyridine derivatives via one-pot multicomponent reactions. Tetrahedron Lett. 2008, 49, 1777–1781.10.1002/chin.200826120Search in Google Scholar
[12] Sarveswari, S.; Vijayakumar, V.; Siva, R.; Priya, R. Synthesis of 4-hydroxy-2(1H)-quinolone derived chalcones, pyrazolines and their antimicrobial, in silico antimalarial evaluations. Appl. Biochem. Biotech. 2015, 175, 43–64.10.1007/s12010-014-1256-9Search in Google Scholar PubMed
[13] Alam, M. M.; Marella, A.; Akhtar, M.; Husain, A.; Yar, M. S.; Shaquiquzzaman, M.; Tanwar, O. P.; Saha, R.; Khanna, S.; Shafi, S. Microwave assisted one pot synthesis of some pyrazole derivatives as a safer anti-inflammatory and analgesic agents. Acta Pol. Pharm.2013, 70, 435–441.Search in Google Scholar
[14] Yang, S. W.; Smotryski, J.; McElroy, W. T.; Tan, Z.; Ho, G.; Tulshian, D.; Greenlee, W. J.; Guzzi, M.; Zhang, X.; Mullins, D. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. Bioorg. Med. Chem. Lett.2012, 22, 235–239.10.1016/j.bmcl.2011.11.023Search in Google Scholar PubMed
[15] Joshi, S. D.; Hallikeri, C. S.; More, U. A.; Basavaraj, H. S.; Kulkarni, V. H. Synthesis and antimicrobial activity of pyrazolo[3,4-b]quinolines containing pyrimidine moiety. J. Heterocycl. Chem. 2011, 21, 69–72.Search in Google Scholar
[16] Alizadeh, A.; Moafi, L.; Ghanbaripour, R.; Abadi, M. H.; Zhu, Z.; Kubicki, M. ChemInform abstract: a new route for the synthesis of 1,3,4-trisubstituted pyrazolo[4,3-c]quinolines via a multicomponent reaction. Tetrahedron2015, 71, 3495–3499.10.1002/chin.201537187Search in Google Scholar
[17] Poursattar Marjani, A.; Khalafy, J.; Salami, F.; Mohammadlou, M. ChemInform abstract: Tin(II) chloride catalyzed synthesis of new pyrazolo[5,4-b]quinolines under solvent-free conditions. Cheminform.2015, 46, 1656–1660.10.1002/chin.201541196Search in Google Scholar
[18] Kato, J.; Ijuin, R.; Aoyama, H.; Yokomatsu, T. Synthesis of poly-substituted pyrazolo[1,5-a]quinolines through one-pot two component cascade reaction. Tetrahedron2014, 70, 2766–2775.10.1016/j.tet.2014.02.081Search in Google Scholar
[19] Zhu, X. T.; Liu, J. Y.; Jiang, B.; Tu, S. J. J. Microwave-assisted aqueous reactions: an efficient route to benzodiazepines. Heterocycl. Chem. 2015, 52, 92–96.10.1002/jhet.1988Search in Google Scholar
[20] Liu, J. Y.; Li, Q. Y.; Jiang, B.; Tu, S. J. Three-component domino reactions providing rapid and efficient routes to fully substituted pyrroles. RSC Advances2013, 3, 5056–5068.10.1039/c3ra40252eSearch in Google Scholar
[21] Liu, J. Y.; Zhang, H.; Feng, B. M.; Jiang, B.; Wang, S. L.; Tu, S. J. A multicomponent synthetic strategy for two-carbon-tethered 1,3-oxathiole–indole pairs. Org. Biomol. Chem. 2012, 10, 5036–5038.10.1039/c2ob25817jSearch in Google Scholar PubMed
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/hc-2018-0131).
©2018 Walter de Gruyter GmbH, Berlin/Boston
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Articles in the same Issue
- Frontmatter
- Preliminary Communications
- Antioxidant, α-glucosidase inhibitory and in vitro antitumor activities of coumarin-benzothiazole hybrids
- Synthesis and properties of tetracyanoquinodimethane derivatives
- Research Articles
- Synthesis, characterization and computational studies of 2-cyano-6-methoxybenzothiazole as a firefly-luciferin precursor
- Synthesis of fluorine-containing phthalocyanines and investigation of the photophysical and photochemical properties of the metal-free and zinc phthalocyanines
- Copper-catalyzed synthesis of 2,3-disubstituted quinazolin-4(3H)-ones from benzyl-substituted anthranilamides
- Synthesis and mass spectrometric fragmentation pattern of 6-(4-chlorophenyl)-N-aryl-4-(trichloromethyl)-4H-1,3,5-oxadiazin-2-amines
- An efficient cascade synthesis of substituted 6,9-dihydro-1H-pyrazolo[3,4-f]quinoline- 8-carbonitriles
- Synthesis and antimicrobial evaluation of isoxazole-substituted 1,3,4-oxadiazoles
Articles in the same Issue
- Frontmatter
- Preliminary Communications
- Antioxidant, α-glucosidase inhibitory and in vitro antitumor activities of coumarin-benzothiazole hybrids
- Synthesis and properties of tetracyanoquinodimethane derivatives
- Research Articles
- Synthesis, characterization and computational studies of 2-cyano-6-methoxybenzothiazole as a firefly-luciferin precursor
- Synthesis of fluorine-containing phthalocyanines and investigation of the photophysical and photochemical properties of the metal-free and zinc phthalocyanines
- Copper-catalyzed synthesis of 2,3-disubstituted quinazolin-4(3H)-ones from benzyl-substituted anthranilamides
- Synthesis and mass spectrometric fragmentation pattern of 6-(4-chlorophenyl)-N-aryl-4-(trichloromethyl)-4H-1,3,5-oxadiazin-2-amines
- An efficient cascade synthesis of substituted 6,9-dihydro-1H-pyrazolo[3,4-f]quinoline- 8-carbonitriles
- Synthesis and antimicrobial evaluation of isoxazole-substituted 1,3,4-oxadiazoles